whatshot

RYTM   $97.71  -1.32% Market Closed After Close 97.71 0.0

Rhythm Pharmaceuticals, Inc.
show_chart Advanced Chart of RYTM
Last Events:

2023-08-06 Trend pattern changed from расширяющаяся формация to нисходящий треугольник.

2023-08-06 Signal in RSI changed from bullish weakening to bullish recovery. RSI indicator is in overbought territory and it heading north. These factors indicate that the upside potential still holds even though the market is overbought. Last signal: entrance to the overbought zone.

2023-08-06 Trend Power changed from almost flat to .

2023-08-06 Trend changed from turning down to flat and down.

2023-08-05 Trend pattern changed from расходящийся треугольник to расширяющаяся формация.

2023-08-05 Signal in RSI changed from bullish recovery to bullish weakening. RSI indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: entrance to the overbought zone.

2023-08-03 Signal in RSI changed from bullish weakening to bullish recovery. RSI indicator is in overbought territory and it heading north. These factors indicate that the upside potential still holds even though the market is overbought. Last signal: entrance to the overbought zone.

2023-08-03 Signal in EMA100 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 16
Target Price Mean 138.13
Mean unverified/preliminary 138.13 / 138.13
Target Price Low / High 105.00 / 160.00
Median / STD DEV 138.00 / 15.41
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None Buy None
rsi Sell None None
macd None None None
stoch None None None
ma20 ActivelyBuy Buy None
ma50 None None None
ma100 None Buy Buy
Candlestick PatternSept. 16, 2026 Bullish Harami - consists of an unusually large black body followed by a small white body contained within large black body. It is considered as a bullish pattern when preceded by a downtrend.
ISIN US76243J1051
ceo Dr. David P. Meeker M.D.
Website https://rhythmtx.com
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.